Formation, Viscosity and Degradation of Artificial Thrombi after Cadaveric-Donor Kidney Transplantation

Summary

Dynamic (VFTV) coagulation and thrombus formation studies were carried out on 15 patients who had undergone cadaveric-donor kidney transplantation and 6 patients with end-stage renal failure awaiting transplantation.

All patients whose kidney graft functioned successfully and without major medical complications showed a coagulation VFTV pattern similar to that of healthy normals. This pattern was present as early as 1 week after transplantation.

Abnormal VFTV pattern (i.a., greatly elevated viscosity), characterised patients awaiting transplantation (6 patients) and 4 patients with serious medical complications following transplantation.

Viscosities of thrombi were two and a half to three-fold higher, and rates of thrombus degradation two to ten fold higher, in the complicated than in the successful kidney transplants.

The viscosity increase is not counteracted by haemodialysis or immunosuppressive drugs.

The difference of VFTV parameters between patients awaiting transplantation and normals and between complicated transplant patients and normals were significant to p <0.005 and p <0.001 respectively.

• References

• 1 Dintenfass L. Effect of velocity gradient on the clotting time of blood and on the consistency of clots formed in vitro. Circulat. Res 18: 349 1966;
• 2 Dintenfass L. Dynamics of blood coagulation. Introducing a new coagulation factor ‘velocity gradient’. Haematologia 01: 387 1967;
• 3 Dintenfass L, Bauer G. E. Dynamic blood coagulation and viscosity and degradation of artificial thrombi in patients with hypertension. Cardiov. Res 04: 50 1970;
• 4 Dintenfass L, Rozenberg M. The influence of the velocity gradient on the in vitro blood coagulation and artificial thrombosis. J. Atheroscler. Res 05: 276 1965;
• 5 Dintenfass L, Sharp A. Dynamic blood coagulation, thrombus formation and degradation in patients with peripheral vascular disease (arteriosclerosis, including diabetics) : and in vitro study. Ann. Surg 170: 984 1969;
• 6 Dintenfass L, Stewart J. H. Formation, consistency and degradation of artificial thrombi in severe renal failure. Effect of ABO blood groups. Thrombos. Diathes. haemorrh. (Stuttg.) 20: 267 1968;
• 7 Rozenberg M. C, Dintenfass L. Thrombus formation in vitro: a rheological and morphological study. Aust. J. exp. Biol. med. Sci 42: 109 1964;
• 8 Rozenberg M. C, Dintenfass L. Platelet aggregation in the variable frequency thrombo- viscometer. Nature 211: 525 1966;
• 9 Sheil A. G. R, Mears D, Kelly G. E, Rogers J. H, Johnson J. R, May J, Charlesworth J, Kalowski S, Stewart J. H. A controlled clinical trial of the use of antilymphocytic globulin as adjuvant therapy for recipients of renal allografts from cadaver donors. Lancet I: 359 1970;
• 10 Sheil A. G. R, Stewart J. H, May J, Johnson J, Tiller D, George G. R. P, Rogers J. H, Storey B. G, Mani M. K, Gibson G. R, Sharjp A, Wyatt K. M, Sands J. R, Loewenthal J. Renal transplantation from cadaver donors. Med. J. Aust 02: 1079 1968;
• 11 Sheil A.G.R, Stewart J. H, Johnson J. R, May J, Storey B. G, Rogers J. H, Charlesworth J. A, Wright R, Sharp a, Johnston J. M, Sands J. R, Loewenthal J. Community treatment of end-stage renal failure by dialysis and renal transplantation from cadaver donors. Lancet 17: 917 1969;
• 12 Stewart J. H, Castaldi P. A. Uraemic bleeding: a reversible platelet defect corrected by dialysis. Quart. J. Med 36: 143 1967;